Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02711345 · OUTCOME

Dose Intensity Received by Participants

A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers. · Source last updated 2019-09-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
milligram per day (mg/day)
Interval / dispersion
Standard Deviation
Time frame
Up to 2.8 years

What was measured

Dose intensity of LTT462 received by treatment group was reported.

Analysis population: The safety set included all participants who had received at least one dose of LTT462.

Groups in this outcome

LTT462 45 mg QD

Participants received 45 mg LTT462 QD as oral capsules.

LTT462 100 mg QD

Participants received 100 mg LTT462 QD as oral capsules.

LTT462 150 mg QD

Participants received 150 mg LTT462 QD as oral capsules.

LTT462 200 mg QD

Participants received 200 mg LTT462 QD as oral capsules.

LTT462 300 mg QD

Participants received 300 mg LTT462 QD as oral capsules.

LTT462 400 mg QD

Participants received 400 mg LTT462 QD as oral capsules.

LTT462 450 mg QD

Participants received 450 mg LTT462 QD as oral capsules.

LTT462 600 mg QD

Participants received 600 mg LTT462 QD as oral capsules.

LTT462 150 mg BID

Participants received 150 mg LTT462 twice daily (BID) as oral capsules.

LTT462 200 mg BID

Participants received 200 mg LTT462 BID as oral capsules.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
LTT462 45 mg QD2
LTT462 100 mg QD3
LTT462 150 mg QD6
LTT462 200 mg QD4
LTT462 300 mg QD8
LTT462 400 mg QD6
LTT462 450 mg QD12
LTT462 600 mg QD6
LTT462 150 mg BID6
LTT462 200 mg BID12

Reported measurements

Source class 1
Values in milligram per day (mg/day) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
LTT462 45 mg QD65.328.74Not reportedNot reportedNot reported
LTT462 100 mg QD98.13.21Not reportedNot reportedNot reported
LTT462 150 mg QD133.921.84Not reportedNot reportedNot reported
LTT462 200 mg QD200.00.00Not reportedNot reportedNot reported
LTT462 300 mg QD272.730.90Not reportedNot reportedNot reported
LTT462 400 mg QD326.781.54Not reportedNot reportedNot reported
LTT462 450 mg QD409.264.88Not reportedNot reportedNot reported
LTT462 600 mg QD468.2171.48Not reportedNot reportedNot reported
LTT462 150 mg BID131.622.08Not reportedNot reportedNot reported
LTT462 200 mg BID178.035.32Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        28.74
        value
        65.3
      2. group Id
        OG001
        spread
        3.21
        value
        98.1
      3. group Id
        OG002
        spread
        21.84
        value
        133.9
      4. group Id
        OG003
        spread
        0.00
        value
        200.0
      5. group Id
        OG004
        spread
        30.90
        value
        272.7
      6. group Id
        OG005
        spread
        81.54
        value
        326.7
      7. group Id
        OG006
        spread
        64.88
        value
        409.2
      8. group Id
        OG007
        spread
        171.48
        value
        468.2
      9. group Id
        OG008
        spread
        22.08
        value
        131.6
      10. group Id
        OG009
        spread
        35.32
        value
        178.0
denoms
  1. counts
    1. group Id
      OG000
      value
      2
    2. group Id
      OG001
      value
      3
    3. group Id
      OG002
      value
      6
    4. group Id
      OG003
      value
      4
    5. group Id
      OG004
      value
      8
    6. group Id
      OG005
      value
      6
    7. group Id
      OG006
      value
      12
    8. group Id
      OG007
      value
      6
    9. group Id
      OG008
      value
      6
    10. group Id
      OG009
      value
      12
    units
    Participants
description
Dose intensity of LTT462 received by treatment group was reported.
dispersion Type
Standard Deviation
groups
  1. description
    Participants received 45 mg LTT462 QD as oral capsules.
    id
    OG000
    title
    LTT462 45 mg QD
  2. description
    Participants received 100 mg LTT462 QD as oral capsules.
    id
    OG001
    title
    LTT462 100 mg QD
  3. description
    Participants received 150 mg LTT462 QD as oral capsules.
    id
    OG002
    title
    LTT462 150 mg QD
  4. description
    Participants received 200 mg LTT462 QD as oral capsules.
    id
    OG003
    title
    LTT462 200 mg QD
  5. description
    Participants received 300 mg LTT462 QD as oral capsules.
    id
    OG004
    title
    LTT462 300 mg QD
  6. description
    Participants received 400 mg LTT462 QD as oral capsules.
    id
    OG005
    title
    LTT462 400 mg QD
  7. description
    Participants received 450 mg LTT462 QD as oral capsules.
    id
    OG006
    title
    LTT462 450 mg QD
  8. description
    Participants received 600 mg LTT462 QD as oral capsules.
    id
    OG007
    title
    LTT462 600 mg QD
  9. description
    Participants received 150 mg LTT462 twice daily (BID) as oral capsules.
    id
    OG008
    title
    LTT462 150 mg BID
  10. description
    Participants received 200 mg LTT462 BID as oral capsules.
    id
    OG009
    title
    LTT462 200 mg BID
param Type
MEAN
population Description
The safety set included all participants who had received at least one dose of LTT462.
reporting Status
POSTED
time Frame
Up to 2.8 years
title
Dose Intensity Received by Participants
type
PRIMARY
unit Of Measure
milligram per day (mg/day)

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice